Columbia Scientists Are Making COVID Antibodies More Adaptable
There are many ways to support our health and resilience from infection. A large focus in biomedical research has been directed to creating effective vaccines, which train the body to attack or acclimate to pathogens. However, vaccines don’t come with zero risk, and those who are immunocompromised may fail to mount an adequate response to them, rendering them less effective.
With advances in science, scientists have been able to extract monoclonal antibodies from recovered patients to help protect at-risk people from pathogens. Unlike vaccines, which train the immune system, monoclonal antibodies directly block pathogens.
Monoclonal antibodies have been used as prophylactics and early intervention against Covid (for those able to get access to them) and other pathogens.
However, during the time it takes for monoclonal antibodies to be extracted from a recovered patient to reach clinical settings, the virus often already has mutated.
That’s what Columbia researchers were seeking to solve. In exciting new research published on July 4, 2025 in Nature, the team showed very promising results of engineered Covid antibodies to protect against new Covid variants.
The Columbia scientists were able to engineer a novel, single molecular tweak to a human antibody to help it adapt as the virus keeps evolving.
Finding an Antibody from a Person Who Recovered from Omricon Variant
The Columbia research team was led by Prof. Dr. David Ho and Prof. Yicheng Guo and researchers Qian Wang and post-doc Ryan Casner, who also works at Sanofi, an AI-powered biopharma company.
The team began by isolating an antibody called 19‑77 from someone who had recovered from an Omicron BA.5 infection.
On its own, this naturally occurring antibody could neutralize many major SARS‑CoV‑2 variants, from Alpha and Delta to Omicron offshoots like BQ.1.1, XBB, BA.2.86, and JN.1.
It recognized a vulnerable site on the virus’s spike protein, the same region the virus uses to bind to our cells. However, the spike region continues to change to help the virus slip past human immune defenses.
Even very strong antibodies can lose their effectiveness when the virus mutates.
A Subtle Change: Targeting an Amino Acid to Alter the Framework
Rather than trying to make the antibody bind even more tightly, the researchers took a different approach. They focused on the framework region of the antibody, which acts like a scaffold supporting the parts that do the virus-binding work.
They found that a single amino acid, called R71, formed a bond that kept the antibody relatively rigid. By changing this residue, a precise, minimal modification, they reduced the bond, giving the antibody’s binding loops more room to move.
This added flexibility made it easier for the antibody to adjust its shape and stay effective against new viral variants with slightly altered spikes.
Big Results
The results were striking. The redesigned version, named 19‑77Δ, was able to neutralize every single variant tested: 36 in total, including newer variants like XEC and LP.8 that are currently concerning researchers.
This strategy didn’t just work for one antibody. The same framework tweak improved potency in several other antibodies from the same family.
What This Means for People
For people who have impaired immune systems, people who are caretakers of someone who is immunocompromised, and those at-risk who have had prior vaccine injuries or concerns, monoclonal antibody therapies may potentially be a promising treatment.
This study suggests a new path forward: designing antibodies that aren’t just strong, but also adaptable, able to respond to the virus’s ongoing changes.
This could help ensure there are still safe options for pre-exposure prevention or early treatment, especially for people for whom Covid remains a significant risk.
Exciting Science and Powerful Metaphor
I can’t believe this isn’t more in the news.
The science is very cool. It’s also a metaphorical reminder that the key to resilience, whether in biology or in life, is often not more force, but more flexibility.
You can find the study here in Nature.
